The Effect of COVID-19 Vaccines (Available in Egypt) on D-Dimer and Platelets Count in Kafr El-Sheikh Governorate

Abstract Background The COVID-19 pandemic, caused by the SARS-CoV-2 virus, led to the development of various vaccines, including mRNA (Pfizer, Moderna), vector (AstraZeneca, Johnson & Johnson), and inactivated virus (Sinopharm, Sinovac) types. Although generally safe, rare cases of thromboembolic events associated with vector vaccines have been reported. Governments, like Egypt, prioritize vaccine distribution. Common side effects include mild reactions, and overall, vaccines play a crucial role in mitigating the pandemic. Aim of the Work This study in Kafr El Sheikh, Egypt, investigates the effects of COVID-19 vaccines on D-dimer levels, platelet counts, and various short-term complications, including general, local, and chest-related issues. Patients and Methods A cross-sectional study at Kafr El Sheikh Chest Hospital involving 88 participants above 18 years assessed the impact of AstraZeneca and Pfizer COVID-19 vaccines. It included medical history, clinical examination, and laboratory investigations, with ethical approval and minimal risks. Statistical analysis utilized SPSS version 20, presenting qualitative and quantitative data. The study found significance at p < 0.05. Results This Kafr El Sheikh study on 88 individuals receiving AstraZeneca and Pfizer COVID-19 vaccines found no significant differences in D-dimer, platelet counts, or chest symptoms between the two groups. AstraZeneca was associated with higher constitutional symptoms, while Pfizer resulted in more pain at the injection site. Overall, both vaccines demonstrated safety. Conclusion This study concludes that the second doses of AstraZeneca and Pfizer COVID- 19 vaccines show similar safety profiles regarding D-dimer, platelet counts, and symptoms. Both vaccines demonstrate overall safety and efficacy, supporting their continued use in mitigating the impact of the pandemic.